Clinical trials: SARS
COVID-19
Study of Efficacy of Different Treatment Regimens of Olokizumab
The primary objective of the study is to evaluate the efficacy and safety of Artlegia (INN: olokizumab) new dosing regimen in patients with moderate coronavirus infection (COVID-19) with signs of hyperinflammation.
- Trial name
- RESET (NCT05187793)
- Testing
- Olokizumab, Standard therapy
- Where
- 5 sites in Russia
- Volunteers
- 198 people
- Sponsor
- R-Pharm
Infection Viral
COVID-19 - SARS-CoV-2 Community Contamination in Children and Adults (Dyn3CEA_Nosocor)
Unlike other respiratory viruses such as influenza and Respiratory Syncytial Virus (RSV) where the child is the essential reservoir and central vector of intrafamilial contamination, the child is likely to be a small player in…
- Trial name
- NCT04664296
- Testing
- Review of medical patient file, Phone call interview
- Where
- France
- Volunteers
- 72 people
- Sponsor
- Hospices Civils de Lyon
COVID-19, SARS-CoV-2
Slovenian National COVID-19 Prevalence Study
The investigators are conducting a national COVID-19 prevalence survey on a sample of 3,000 inhabitants that were randomly selected from the Slovenian population.
- Trial name
- SLO-COVID-19 (NCT04376996)
- Testing
- NO intervention planned due to the observational study design - only a diagnostic testing
- Where
- Slovenia
- Volunteers
- 3,000 people
- Sponsor
- University of Ljubljana
COVID-19 Pneumonia, Tocilizumab
Tocilizumab in Covid-19 Penumonia in Buenos Aires City
We conducted a retrospective observational study of adult participants receiving only SOC (dexamethasone 8 mg or its equivalent plus oxygen, HNFO or eventual IMV) versus participants receiving SOC plus TCZ (8mg/kg as a single…
- Trial name
- NCT05057962
- Where
- Argentina
- Volunteers
- 100 people
- Sponsor
- Sanatorio Finochietto
SARS CoV 2 Infection, Cancer
Mortality of Cancer Surgery During SARS CoV2 Pandemic
The impact of cancer surgery during covid epidemic is not clear. The published reports show contradictory findings that extend from no change in mortality to increased mortality, further no data on exposure and outcome of health…
- Trial name
- NCT05240378
- Testing
- Surgery
- Where
- India
- Volunteers
- 1,576 people
- Sponsor
- Banaras Hindu University
COVID-19
Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives
Coronavirus disease 2019 (COVID-19) ,caused by the newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus, has shown substantial global spread affecting over 2 million people and claiming over 120,000…
- Trial name
- NCT04357535
- Testing
- Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)
- Where
- Saudi Arabia
- Volunteers
- 314 people
- Sponsor
- Hakeam Abdulaziz Hakeam
Healthy Adult Volunteers
Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination
The investigators conduct a prospective analysis to compare homologous and heterologous adenovirus vector ChAdOx1-nCov-19 (Astra-Zeneca) or SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine inoculation.
- Trial name
- NCT05074368
- Testing
- ChAdOx1-nCov-19 (Astra-Zeneca), SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine
- Where
- Taiwan
- Volunteers
- 499 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
COVID-19, SARS-CoV-2
The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms
The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus. Multicenter randomized, double-blind, placebo-controlled, non-commercial clinical trial
- Trial name
- COV-PREVENT (NCT04854759)
- Testing
- Amantadine Hydrochloride
- Where
- 8 sites in Poland
- Volunteers
- 200 people
- Sponsor
- Independent Public Clinical Hospital No. 4 in Lublin
Covid19, Corona Virus Infection
T Cells Response to SARS COV 2 Peptides
The analysis method described in this protocol is a novel simple plausible immunological approach which is non-invasive, high throughput, real-time quantitative monitoring of metabolic activity (MA) profiles of fresh Peripheral…
- Trial name
- NCT04573348
- Testing
- Savicell's ImmunoBiopsy™
- Where
- Israel
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Savicell Diagnostics Ltd
Corona Virus Infection, SARS-CoV 2
Kidney in Coronavirus Disease 2019 Registry
The SARS-CoV-2 virus is a virus newly identified in January 2020. The WHO defined COVID-19 as a health emergency of international importance.
- Trial name
- KidneyCOVID19 (NCT04797091)
- Testing
- Retrospective data collection
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University of Cologne
Covid-19 Prevention
A Study of Ad26.COV2.S in Adults (COVID-19)
The purpose of the study is to assess the safety, reactogenicity, and immunogenicity of Ad26.COV2.S at 2 dose levels, administered intramuscularly (IM) as a single-dose or 2-dose schedule, with a single booster vaccination…
- Trial name
- NCT04436276
- Testing
- Ad26.COV2.S
- Where
- 12 sites in United States, Belgium
- Volunteers
- 1,085 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Systemic Inflammation, Neuroinflammation
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
Background: COVID-19 can cause problems in different parts of the body. For most people, it causes fevers or trouble breathing. Some people might not recover all the way.
- Conditions
- Systemic Inflammation, Neuroinflammation, Microvascular Thrombosis
- Trial name
- NCT05350774
- Testing
- IV normal saline, IV immunoglobulin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Anxiety Depression, Post Traumatic Stress Disorder
Neuropsychological Sequelae and Long COVID-19 Fatigue
An association of fatigue with post-viral neuropsychological disturbs has been reported. Among patients hospitalized with COVID-19 there is an increased incidence of anxiety and depression symptoms.
- Conditions
- Anxiety Depression, Post Traumatic Stress Disorder, Mental Fatigue, COVID-19
- Trial name
- PostCoV2Psy (NCT05323318)
- Testing
- Neuropsychological Sequelae
- Where
- 6 sites in Portugal
- Volunteers
- 200 people
- Sponsor
- Centro Hospitalar Universitario do Algarve
Autoimmune or Autoinflammatory Diseases, HIV
Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People
Prospective, multicenter, non-comparative cohort study of immunocompromised people vaccinated against Covid-19 with the aim to know the humoral and cellular response to BNT162b2 vaccination against SARS-CoV-2 variants.
- Conditions
- Autoimmune or Autoinflammatory Diseases, HIV, Multiple Sclerosis, Solid Tumors or Cancers
- Trial name
- COVIVAC-ID (NCT04844489)
- Testing
- Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19
- Where
- France
- Volunteers
- 377 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID19
SARS-CoV-2 (COVID-19) Detection Using the Breath Analizer TeraSystem
The purpose of the study is to verify the sensibility and accuracy of a rapid detection test for SARS-CoV-2 in breath samples analyzed by the breath detector analyzer TeraSystem, comparing with PCR tests.
- Trial name
- NCT04497610
- Testing
- Breath sample
- Where
- Costa Rica
- Volunteers
- healthy volunteers welcome
- Sponsor
- Instituto Costarricense de Investigaciones Clínicas ICIC
SARS-CoV-2, COVID19
CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort
The overall objective of the study is to determine the therapeutic effect and tolerance of Eculizumab in patients with moderate, severe pneumonia or critical pneumonia associated with Coronavirus disease 2019 (COVID-19).
- Trial name
- CORIMUNO19-ECU (NCT04346797)
- Testing
- Eculizumab
- Where
- 3 sites in France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19
Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study
Convalescent plasma has been shown to be safe and effective for treatment of several diseases. Preliminary data indicates that it is safe and effective for treatment of COVID.
- Trial name
- NCT04384497
- Testing
- SARS-CoV-2 convalescent plasma
- Where
- 2 sites in Sweden
- Volunteers
- 10 people
- Sponsor
- Joakim Dillner
CoronaVirus Disease-2019 (COVID-19)
Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Lung failure is the main cause of death related to COVID-19 infection.
- Trial name
- NCT04644120
- Testing
- ABBV-47D11, ABBV-2B04
- Where
- 18 sites in United States, Hungary and 3 more
- Volunteers
- 25 people
- Sponsor
- AbbVie
COVID-19 Pandemic
A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine
This study is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the safety and immunogenicity of SCTV01E in population of different ages who have been vaccinated against COVID-19.
- Trial name
- SCTV01E (NCT05652543)
- Testing
- SCTV01E
- Where
- 4 sites in China
- Volunteers
- 518 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Severe Acute Respiratory Syndrome (SARS-CoV-2 Virus)
Bio-Manguinhos/Fiocruz COVID-19 (mRNA) Vaccine Booster
This is a descriptive, open-label, multicenter, non-randomized, uncontrolled phase I clinical study to evaluate the safety, reactogenicity, and immunogenicity of the COVID-19 Vaccine (mRNA) - Bio-Manguinhos/Fiocruz at doses of 25…
- Trial name
- NCT07640308
- Testing
- Grupo 1 - dose 25 μg, Group 2 - 50 μg dose, Group 3 - 100 μg
- Volunteers
- 90 people
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)